美国 · SEC FORM 4
Protara Therapeutics, Inc.
TARA · Nasdaq · CIK 0001359931 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
7 同一窗口内观察到的 Form 4 交易行
1 sales · 6 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-05-14 · Levy Richard S.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 5,791,421
- 上期报告
- 4,417,095
- 日均成交量
- 1,992,294
- 回补天数
- 2.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-05-14 | Levy Richard S | 买入 (P) | Common Stock | 20,000 | USD 3.19 | USD 63,800 | SEC 申报 ↗ |
| 2025-05-14 | Levy Richard S | 买入 (P) | Common Stock | 20,000 | USD 3.19 | USD 63,800 | SEC 申报 ↗ |
| 2022-09-15 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 7,300 | USD 3.80 | USD 27,740 | SEC 申报 ↗ |
| 2022-09-14 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 16,600 | USD 3.98 | USD 66,068 | SEC 申报 ↗ |
| 2022-08-11 | Shefferman Jesse | 买入 (P) | Common Stock | 9,065 | USD 3.84 | USD 34,810 | SEC 申报 ↗ |
| 2022-06-30 | BESHAR LUKE M | 买入 (P) | Common Stock | 10,000 | USD 3.10 | USD 31,000 | SEC 申报 ↗ |
| 2022-04-08 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 7,791 | USD 4.80 | USD 37,397 | SEC 申报 ↗ |
| 2022-04-08 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 7,791 | USD 4.80 | USD 37,397 | SEC 申报 ↗ |
| 2022-04-07 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 2,345 | USD 4.74 | USD 11,115 | SEC 申报 ↗ |
| 2022-04-07 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 2,345 | USD 4.74 | USD 11,115 | SEC 申报 ↗ |
| 2022-03-14 | BESHAR LUKE M | 买入 (P) | Common Stock | 10,000 | USD 4.25 | USD 42,500 | SEC 申报 ↗ |
| 2022-03-10 | BESHAR LUKE M | 买入 (P) | Common Stock | 10,000 | USD 4.46 | USD 44,600 | SEC 申报 ↗ |
| 2022-01-28 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 24,031 | USD 4.96 | USD 119,194 | SEC 申报 ↗ |
| 2021-12-29 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 4,500 | USD 6.98 | USD 31,410 | SEC 申报 ↗ |
| 2021-12-28 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 7,091 | USD 6.36 | USD 45,099 | SEC 申报 ↗ |
Form 4 申报证据
23 transaction lines in the latest 365-day window; 224 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse | 赠与 (G) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-29 | Shefferman Jesse | 卖出 (S) | Common Stock | 215,687 | USD 4.09 | USD 882,160 | SEC 申报 ↗ |
| 2026-06-29 | Shefferman Jesse | 期权行权/转换 (M) | Common Stock | 215,687 | USD 1.91 | USD 411,962 | SEC 申报 ↗ |
展开近期 Form 4 证据 (20 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse | 赠与 (G) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-29 | Shefferman Jesse | 卖出 (S) | Common Stock | 215,687 | USD 4.09 | USD 882,160 | SEC 申报 ↗ |
| 2026-06-29 | Shefferman Jesse | 期权行权/转换 (M) | Common Stock | 215,687 | USD 1.91 | USD 411,962 | SEC 申报 ↗ |
| 2026-06-02 | CONKLING WILLIAM | 代扣税 (F) | Common Stock | 6,008 | USD 4.34 | USD 26,075 | SEC 申报 ↗ |
| 2026-04-08 | Zummo Jacqueline | 卖出 (S) | Common Stock | 1,134 | USD 5.40 | USD 6,124 | SEC 申报 ↗ |
| 2026-04-01 | Zummo Jacqueline | 卖出 (S) | Common Stock | 22,598 | USD 5.26 | USD 118,865 | SEC 申报 ↗ |
| 2026-01-26 | Zummo Jacqueline | 代扣税 (F) | Common Stock | 3,724 | USD 6.67 | USD 24,839 | SEC 申报 ↗ |
| 2026-01-26 | Shefferman Jesse | 代扣税 (F) | Common Stock | 8,732 | USD 6.67 | USD 58,242 | SEC 申报 ↗ |
| 2026-01-26 | Fry Hannah | 代扣税 (F) | Common Stock | 1,457 | USD 6.67 | USD 9,718 | SEC 申报 ↗ |
| 2026-01-26 | Fabbio Patrick | 代扣税 (F) | Common Stock | 3,261 | USD 6.67 | USD 21,751 | SEC 申报 ↗ |
| 2026-01-20 | Zummo Jacqueline | 代扣税 (F) | Common Stock | 6,578 | USD 5.60 | USD 36,837 | SEC 申报 ↗ |
| 2026-01-20 | Shefferman Jesse | 代扣税 (F) | Common Stock | 16,322 | USD 5.60 | USD 91,403 | SEC 申报 ↗ |
| 2026-01-20 | Fry Hannah | 代扣税 (F) | Common Stock | 2,132 | USD 5.60 | USD 11,939 | SEC 申报 ↗ |
| 2026-01-20 | Fabbio Patrick | 代扣税 (F) | Common Stock | 3,063 | USD 5.60 | USD 17,153 | SEC 申报 ↗ |
| 2026-01-16 | Zummo Jacqueline | 奖励/授予 (A) | Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-16 | Shefferman Jesse | 奖励/授予 (A) | Common Stock | 87,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-16 | Nicacio Leonardo Viana | 奖励/授予 (A) | Common Stock | 26,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-16 | Fry Hannah | 奖励/授予 (A) | Common Stock | 9,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-16 | Fabbio Patrick | 奖励/授予 (A) | Common Stock | 28,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-16 | CONKLING WILLIAM | 奖励/授予 (A) | Common Stock | 26,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TARA |
| CIK | 0001359931 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 224 transaction lines from 2020-01-09 to 2026-06-30 44 P purchase lines · 82 S sale lines · 98 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.